Targeting the Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer

Abstract

Androgen Deprivation Therapy (ADT) remains the first-line treatment option for patients with advanced metastatic prostate cancer. However, despite initial responses to ADT, the majority of patients develop resistance to ADT and progress to castration resistant prostate cancer (CRPC). The mechanisms of resistance to ADT are poorly understood and remains an urgent unmet need in prostate cancer research. It has been hypothesized that AR splice variants play acausal role in conferring endocrine resistance in prostate cancer. ARv7 is the most frequently expressed AR splice variant in CRPC and is associated with poor prognosis and resistance to ADT. The overarching goal of this study is to further delineate the role and mechanisms governing ARv7 activity in CRPC. We hypothesize that the use of AR N-terminal disrupting inhibitors may target the ARv7 and demonstrate increased effectiveness in the treatment of CRPC.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1193687

Entities

People

  • Irene Lee

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Cancer
  • Castration
  • Cell Line
  • Cells
  • Chromosome Structures
  • Department Of Defense
  • Information Operations
  • Inhibitors
  • Maryland
  • Neoplasms
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Resistance
  • Small Molecules
  • Targeting
  • Targets
  • Technology Transfer

Fields of Study

  • Biology
  • Medicine

Readers

  • Prostate Cancer Biology.